Literature DB >> 28352664

Intranasal siRNA administration reveals IGF2 deficiency contributes to impaired cognition in Fragile X syndrome mice.

Marta Pardo1,2, Yuyan Cheng1,2, Dmitry Velmeshev1, Marco Magistri1, Hagit Eldar-Finkelman3, Ana Martinez4, Mohammad A Faghihi1, Richard S Jope1,2, Eleonore Beurel1,2.   

Abstract

Molecular mechanisms underlying learning and memory remain imprecisely understood, and restorative interventions are lacking. We report that intranasal administration of siRNAs can be used to identify targets important in cognitive processes and to improve genetically impaired learning and memory. In mice modeling the intellectual deficiency of Fragile X syndrome, intranasally administered siRNA targeting glycogen synthase kinase-3β (GSK3β), histone deacetylase-1 (HDAC1), HDAC2, or HDAC3 diminished cognitive impairments. In WT mice, intranasally administered brain-derived neurotrophic factor (BDNF) siRNA or HDAC4 siRNA impaired learning and memory, which was partially due to reduced insulin-like growth factor-2 (IGF2) levels because the BDNF siRNA- or HDAC4 siRNA-induced cognitive impairments were ameliorated by intranasal IGF2 administration. In Fmr1-/- mice, hippocampal IGF2 was deficient, and learning and memory impairments were ameliorated by IGF2 intranasal administration. Therefore intranasal siRNA administration is an effective means to identify mechanisms regulating cognition and to modulate therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28352664      PMCID: PMC5358485          DOI: 10.1172/jci.insight.91782

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  53 in total

Review 1.  Nanoparticles for direct nose-to-brain delivery of drugs.

Authors:  Alpesh Mistry; Snjezana Stolnik; Lisbeth Illum
Journal:  Int J Pharm       Date:  2009-06-23       Impact factor: 5.875

Review 2.  Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases.

Authors:  Eleonore Beurel; Steven F Grieco; Richard S Jope
Journal:  Pharmacol Ther       Date:  2014-11-27       Impact factor: 12.310

Review 3.  Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.

Authors:  Katrina J Falkenberg; Ricky W Johnstone
Journal:  Nat Rev Drug Discov       Date:  2014-08-18       Impact factor: 84.694

Review 4.  Judging a protein by more than its name: GSK-3.

Authors:  J R Woodgett
Journal:  Sci STKE       Date:  2001-09-18

Review 5.  BDNF and memory processing.

Authors:  Pedro Bekinschtein; Martin Cammarota; Jorge H Medina
Journal:  Neuropharmacology       Date:  2013-05-18       Impact factor: 5.250

6.  Chromatin acetylation, memory, and LTP are impaired in CBP+/- mice: a model for the cognitive deficit in Rubinstein-Taybi syndrome and its amelioration.

Authors:  Juan M Alarcón; Gaël Malleret; Khalid Touzani; Svetlana Vronskaya; Shunsuke Ishii; Eric R Kandel; Angel Barco
Journal:  Neuron       Date:  2004-06-24       Impact factor: 17.173

Review 7.  Glycogen synthase kinase-3 inhibitors: Rescuers of cognitive impairments.

Authors:  Margaret K King; Marta Pardo; Yuyan Cheng; Kimberlee Downey; Richard S Jope; Eléonore Beurel
Journal:  Pharmacol Ther       Date:  2013-07-31       Impact factor: 12.310

8.  HDAC2 negatively regulates memory formation and synaptic plasticity.

Authors:  Ji-Song Guan; Stephen J Haggarty; Emanuela Giacometti; Jan-Hermen Dannenberg; Nadine Joseph; Jun Gao; Thomas J F Nieland; Ying Zhou; Xinyu Wang; Ralph Mazitschek; James E Bradner; Ronald A DePinho; Rudolf Jaenisch; Li-Huei Tsai
Journal:  Nature       Date:  2009-05-07       Impact factor: 49.962

9.  A critical role for IGF-II in memory consolidation and enhancement.

Authors:  Dillon Y Chen; Sarah A Stern; Ana Garcia-Osta; Bernadette Saunier-Rebori; Gabriella Pollonini; Dhananjay Bambah-Mukku; Robert D Blitzer; Cristina M Alberini
Journal:  Nature       Date:  2011-01-27       Impact factor: 49.962

10.  A pivotal role of GSK-3 in synaptic plasticity.

Authors:  Clarrisa A Bradley; Stéphane Peineau; Changiz Taghibiglou; Celine S Nicolas; Daniel J Whitcomb; Zuner A Bortolotto; Bong-Kiun Kaang; Kwangwook Cho; Yu Tian Wang; Graham L Collingridge
Journal:  Front Mol Neurosci       Date:  2012-02-15       Impact factor: 5.639

View more
  11 in total

1.  Brain Penetrable Histone Deacetylase 6 Inhibitor SW-100 Ameliorates Memory and Learning Impairments in a Mouse Model of Fragile X Syndrome.

Authors:  Alan P Kozikowski; Sida Shen; Marta Pardo; Maurício T Tavares; Dora Szarics; Veronick Benoy; Chad A Zimprich; Zsófia Kutil; Guiping Zhang; Cyril Bařinka; Matthew B Robers; Ludo Van Den Bosch; James H Eubanks; Richard S Jope
Journal:  ACS Chem Neurosci       Date:  2018-12-14       Impact factor: 4.418

2.  Inhibition of histone deacetylase 3 by MiR-494 alleviates neuronal loss and improves neurological recovery in experimental stroke.

Authors:  Haiping Zhao; Guangwen Li; Sijia Zhang; Fangfang Li; Rongliang Wang; Zhen Tao; Qingfeng Ma; Ziping Han; Feng Yan; Junfen Fan; Lingzhi Li; Xunming Ji; Yumin Luo
Journal:  J Cereb Blood Flow Metab       Date:  2019-09-11       Impact factor: 6.200

3.  Selective inhibition of glycogen synthase kinase 3α corrects pathophysiology in a mouse model of fragile X syndrome.

Authors:  Patrick K McCamphill; Laura J Stoppel; Rebecca K Senter; Michael C Lewis; Arnold J Heynen; David C Stoppel; Vinay Sridhar; Katie A Collins; Xi Shi; Jen Q Pan; Jon Madison; Jeffrey R Cottrell; Kimberly M Huber; Edward M Scolnick; Edward B Holson; Florence F Wagner; Mark F Bear
Journal:  Sci Transl Med       Date:  2020-05-20       Impact factor: 17.956

Review 4.  Deciphering the roles of glycogen synthase kinase 3 (GSK3) in the treatment of autism spectrum disorder and related syndromes.

Authors:  Mahdi Rizk; Zahraa Saker; Hisham F Bahmad; Sanaa Nabha; Hayat Harati; Youssef Fares
Journal:  Mol Biol Rep       Date:  2021-03-01       Impact factor: 2.316

5.  Anti-inflammatory IL-10 administration rescues depression-associated learning and memory deficits in mice.

Authors:  Ryan J Worthen; Susan S Garzon Zighelboim; Camila S Torres Jaramillo; Eleonore Beurel
Journal:  J Neuroinflammation       Date:  2020-08-22       Impact factor: 8.322

6.  Neuronal fragile X mental retardation protein activates glial insulin receptor mediated PDF-Tri neuron developmental clearance.

Authors:  Dominic J Vita; Cole J Meier; Kendal Broadie
Journal:  Nat Commun       Date:  2021-02-19       Impact factor: 14.919

Review 7.  Mechanisms and Therapeutic Implications of GSK-3 in Treating Neurodegeneration.

Authors:  Ido Rippin; Hagit Eldar-Finkelman
Journal:  Cells       Date:  2021-01-29       Impact factor: 6.600

Review 8.  Insulin-Like Growth Factor 2 As a Possible Neuroprotective Agent and Memory Enhancer-Its Comparative Expression, Processing and Signaling in Mammalian CNS.

Authors:  Alexander Beletskiy; Ekaterina Chesnokova; Natalia Bal
Journal:  Int J Mol Sci       Date:  2021-02-12       Impact factor: 5.923

9.  Discovery and Design of Novel Small Molecule GSK-3 Inhibitors Targeting the Substrate Binding Site.

Authors:  Ido Rippin; Netaly Khazanov; Tania Kudinov; Eva Berent; Sara Melisa Arciniegas Ruiz; Daniele Marciano; Laura Levy; Arie Gruzman; Hanoch Senderowitz; Hagit Eldar-Finkelman
Journal:  Int J Mol Sci       Date:  2020-11-18       Impact factor: 5.923

10.  Identification of a hippocampal lncRNA-regulating network in cognitive dysfunction caused by chronic cerebral hypoperfusion.

Authors:  Zhao-Hui Yao; Jing Wang; Bing-Zhen Shen; Yu-Tong Li; Xiao-Li Yao; Shao-Feng Zhang; Yong Zhang; Ji-Chang Hu; Yan-Chun Xie
Journal:  Aging (Albany NY)       Date:  2020-10-11       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.